Trial Profile
A Multicenter, Retrospective Study Investigating the Efficacy and Safety of Sunitinib in Chinese Patients with Advanced Pancreatic Neuroendocrine Tumors (pNETs)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Jan 2018
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- 09 Jan 2018 New trial record